Business
Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline
BOSTON, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing
About this update from Praxis Precision Medicines, Inc.
[{"type":"text","content":"BOSTON, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, today announced its participation in the upcoming International Epilepsy Congress (IEC), taking place August 30–September 3, 2025, in Lisbon, Portugal. In addition to showcasing recent topline results from the RADIANT study in focal onset seizures (FOS), Praxis will share the latest preclinical and clinical data and progress on trials across its precision epilepsy pipeline over twelve presentations at the event: Vormatrigine: Showcasing positive topline RADIANT results in FOS, updates from the first-in-human Phase 1 study, and further preclinical and clinical data supporting the accelerated advancement of the POWER1 pivotal study and the wider ENERGY program, poised to transform the epilepsy landscape.Relutrigine: Sharing the latest from the EMBOLD study in SCN2A- and SCN8A-DEE, the EMERALD registrational study in broad DEEs, as well as preclinical data emphasizing the promising potential of relutrigine to address significant unmet needs across the spectrum of DEEs.Elsunersen: Highlighting the ongoing EMBRAVE3 registrational study, alongside updates from the global emergency use cases demonstrating potential for long-term benefits, consistent safety and tolerability, and potential for further enhancement by precision sodium channel modulation in patients with early onset SCN2A gain-of-function DEE. “IEC is an important moment to showcase how our science is translating into meaningful potential for people living with epilepsy,” said Steven Petrou, chief scientific officer and co-founder of Praxis. “We look forward to engaging with the clinical and advocacy communities in Lisbon to share progress and highlight the strength of our patient-centered approach to epilepsy. This includes the latest from the RADIANT study in FOS, further validating the differentiation of our precision epilepsy platform, as well as updates on our rapidly enrolling studies. These advancements offer exciting insights into the therapeutic potential of our pipeline and reinforce our commitment to developing transformative treatments for people with epilepsy.” Praxis will be present at Booth #435 and adjoining scientific exhibit, where attendees can conn...